0001104659-24-060568.txt : 20240513 0001104659-24-060568.hdr.sgml : 20240513 20240513162531 ACCESSION NUMBER: 0001104659-24-060568 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20240513 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NeuBase Therapeutics, Inc. CENTRAL INDEX KEY: 0001173281 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 465622433 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35963 FILM NUMBER: 24939445 BUSINESS ADDRESS: STREET 1: 350 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 BUSINESS PHONE: 412-763-3350 MAIL ADDRESS: STREET 1: 350 TECHNOLOGY DRIVE CITY: PITTSBURGH STATE: PA ZIP: 15219 FORMER COMPANY: FORMER CONFORMED NAME: Ohr Pharmaceutical Inc DATE OF NAME CHANGE: 20090819 FORMER COMPANY: FORMER CONFORMED NAME: BBM HOLDINGS, INC. DATE OF NAME CHANGE: 20070402 FORMER COMPANY: FORMER CONFORMED NAME: PRIME RESOURCE INC DATE OF NAME CHANGE: 20020513 8-K 1 tm2414283d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 13, 2024

NeuBase Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		001-35963		46-5622433
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

350 Technology Drive, Pittsburgh, PA		15219
(Address of Principal Executive Offices)		(Zip Code)

	(412) 763-3350
	(Registrant’s Telephone Number, Including Area Code)

	N/A
	(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	NBSE	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.07. Submission of Matters to a Vote of Security Holders.

On May 13, 2024, NeuBase Therapeutics, Inc. (the “Company”) convened and adjourned a Special Meeting of Stockholders (the “Special Meeting”). At the Special Meeting, a total of 1,336,544 shares, or 35.63% of the shares of the Company’s common stock, par value $0.0001 per share, issued and outstanding as of March 28, 2024, which is the record date for the Special Meeting, were represented virtually or by proxy, constituting a quorum.

At the Special Meeting, the Company’s stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on April 9, 2024 (the “Proxy Statement”) and is set forth below.

Proposal No. 1: To approve the liquidation and dissolution of the Company and the plan of liquidation and dissolution of the Company (the “Plan of Dissolution”), which, if approved, will authorize the Board of Directors of the Company to liquidate and dissolve the Company in accordance with the Plan of Dissolution (the “Dissolution Proposal”).

Proposal No. 2: To approve an adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve the Dissolution Proposal (the “Adjournment Proposal”).

As there were not sufficient votes to approve the Dissolution Proposal at the time of the Special Meeting, the sole item of business presented to the stockholders for consideration at the Special Meeting was a vote on the Adjournment Proposal. The voting results for the Adjournment Proposal are set forth below.

For		Against		Abstentions
1,252,481		81,972		2,091

In accordance with the authority granted pursuant to the Adjournment Proposal, the Special Meeting was adjourned with respect to the Dissolution Proposal to solicit additional proxies in favor of the Dissolution Proposal. As announced at the Special Meeting, the Special Meeting will reconvene May 22, 2024 at 8:30 a.m. Eastern Time. The live webcast for the Special Meeting will be available by visiting www.proxydocs.com/NBSE. The record date for the Special Meeting will remain March 28, 2024.

Forward-Looking Statements

Except for the factual statements made herein, information contained in this Current Report on Form 8-K consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects or future events, as well as words such as “believes,” “intends,” “expects,” “plans” and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that the Company will receive sufficient votes to approve the Dissolution Proposal. Reference is also made to other factors detailed from time to time in the Company’s periodic reports filed with the SEC, including the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. The forward-looking statements contained in this Current Report on Form 8-K speak only as of the date of this Current Report on Form 8-K and the Company assumes no obligation to publicly update any forward-looking statements to reflect changes in information, events or circumstances after the date of this Current Report on Form 8-K, unless required by law.

Additional Information and Where to Find It

In connection with the Special Meeting, the Company filed the Proxy Statement with the SEC, which was mailed to the Company’s stockholders as of the record date for the Special Meeting. STOCKHOLDERS AND OTHER INTERESTED PERSONS ARE ADVISED TO READ THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS THERETO, BECAUSE IT CONTAINS IMPORTANT INFORMATION ABOUT THE MATTERS BEFORE THE STOCKHOLDERS AT THE SPECIAL MEETING. The Company’s stockholders may also obtain copies of the Proxy Statement and all other relevant documents filed or that will be filed with the SEC in connection with the Special Meeting, without charge, once available, at the SEC website at http://www.sec.gov or by directing a request the Secretary of NeuBase Therapeutics, Inc., 350 Technology Drive, Pittsburgh, Pennsylvania 15219.

Participants in the Solicitation

The Company and certain of its respective directors, executive officers and other members of management and employees may be deemed participants in the solicitation of proxies of the Company’s stockholders in connection with the Special Meeting. Stockholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of the Company in its annual report on form 10-K for the fiscal year ended September 30, 2022, which was filed with the SEC on December 21, 2022. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to stockholders in connection with the Special Meeting and other matters to be voted at the Special Meeting are set forth in the definitive proxy statement for the Special Meeting.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
104		Cover Page Interactive Data File, formatting Inline Extensible Business Reporting Language (iXBRL).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	NEUBASE THERAPEUTICS, INC.
	(Registrant)

Date: May 13, 2024	By:	/s/ Todd P. Branning
		Todd P. Branning
		Interim Chief Executive Officer and Chief Financial Officer (Principal Executive, Financial and Accounting Officer)

EX-101.SCH 2 nbse-20240513.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 nbse-20240513_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 4 nbse-20240513_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT

Cover	May 13, 2024
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	May 13, 2024
Entity File Number	001-35963
Entity Registrant Name	NeuBase Therapeutics, Inc.
Entity Central Index Key	0001173281
Entity Tax Identification Number	46-5622433
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	350 Technology Drive
Entity Address, City or Town	Pittsburgh
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	15219
City Area Code	412
Local Phone Number	763-3350
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	NBSE
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://neubasetherapeutics.com/role/Cover Cover Cover 1 false false All Reports Book All Reports nbse-20240513.xsd nbse-20240513_lab.xml nbse-20240513_pre.xml tm2414283d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2414283d1_8k.htm": { "nsprefix": "NBSE", "nsuri": "http://neubasetherapeutics.com/20240513", "dts": { "schema": { "local": [ "nbse-20240513.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "nbse-20240513_lab.xml" ] }, "presentationLink": { "local": [ "nbse-20240513_pre.xml" ] }, "inline": { "local": [ "tm2414283d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://neubasetherapeutics.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-05-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414283d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-05-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2414283d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://neubasetherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-24-060568-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-060568-xbrl.zip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�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tm2414283d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001173281 2024-05-13 2024-05-13 iso4217:USD shares iso4217:USD shares false 0001173281 8-K 2024-05-13 NeuBase Therapeutics, Inc. DE 001-35963 46-5622433 350 Technology Drive Pittsburgh PA 15219 412 763-3350 false false false false Common Stock, par value $0.0001 per share NBSE NASDAQ false